Hansa Biopharma AB
OTC: HNSBF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Renée Julie Elisabet Aguiar-Lucander
- Employees
- 125
- Headquarters
- Lund, Sweden
- IPO year
- 2015
- Market cap
- $245.8M
- Website
- https://www.hansabiopharma.com
Loading HNSBF…
Loading profile data…Frequently asked questions about HNSBF
What does Hansa Biopharma AB (HNSBF) do?
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitizatio...
Where does HNSBF trade?
Hansa Biopharma AB (HNSBF) trades on the Other OTC.
What sector is HNSBF in?
Hansa Biopharma AB (HNSBF) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Hansa Biopharma AB?
Renée Julie Elisabet Aguiar-Lucander is the chief executive officer of Hansa Biopharma AB (HNSBF).
Where is Hansa Biopharma AB headquartered?
Hansa Biopharma AB is headquartered in Sweden.
Does HNSBF pay a dividend?
Hansa Biopharma AB (HNSBF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HNSBF go public?
Hansa Biopharma AB (HNSBF) completed its initial public offering in 2015.